Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Viracta Therapeutics, Inc.

$0.01

0 (-8.6%)

D 29Pipeline Score Richly Valued Biotech · Clinical
Market Cap
6.56 M
EPS
-1.10
P/E Ratio
-
Value Trade
4.26 K
SEC Financials
Q3 2024

  • Dilution Risk

    95%

  • R&D Expenses

    7.18 M

  • Total Assets

    21.96 M

  • Total Liabilities

    28.57 M

  • Equity

    -6.62 M

-8.84 %
Week
-17.5 %
1 Month
-25 %
3 Month
-64.89 %
6 Month
-99.04 %
5 Year
-100 %
All Time
Cash Data
Critical

  • Cash Position

    21.13 M

  • Monthly Burn

    3.40 M

  • Runway

    0 mo

  • Burn Trend

    Stable

  • SEC Filing

    Nov 13, 2024
Overview
Volume
484.03 K
52 Week Range
0.01 - 1.31
% held by Insiders
0.03 %
% held by Institutions
0.31 %
Enterprise Value
-3.54 M
Total Shares
39.74 M
Short %
0.01 %
Float Shares
28.69 M
Company Description
Founded:2005

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
NDA Filing example
Nana-val relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL), other EBV-positive cancers
NDA
—

Subscribe to access the data.

Nanomedicine
Oncology
Nana-val relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL), other EBV-positive cancers
NDA
—

Subscribe to access the data.

Nanomedicine
Oncology
Nana-val relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL), other EBV-positive cancers
NDA
—

Subscribe to access the data.

Nanomedicine
Oncology
Unlock Upcoming Catalyst data
Unlock the full Catalyst Timeline
Past FDA Catalysts & PDUFA Decisions
Date Drug Catalyst Stage Outcome Reaction Event Move % Best Trade %
2024-12-31
Nana-val
Phase 1/2 data readout
Phase 1/2
—
–
–
–
2024-12-31
Nana-val
Phase 1/2 data readout
Phase 1/2
—
–
–
–
2024-12-31
Nana-val
Phase 1/2 data readout
Phase 1/2
—
–
–
–
Unlock 1 more historical catalysts
Drug Pipeline Intelligence
D29
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
5
Drugs Scored
0.2x
rNPV / MCap
Top 35%
Micro Cap
(rank 601 of 923)
Percentile Rank
Viracta Therapeutics, Inc. faces pipeline headwinds (29/100), with $1.6B risk-adjusted pipeline value, led by Vosaroxin in Leukemia (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Vosaroxin
Small molecule		Acute Myeloid LeukemiaPhase 3NCT0333834846% $745M COMPLETED 720 - -Oct 31, 2019 -Oct 28, 2020
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Nana-val
EBV-associated cancers
Phase 1b/2
2023-10-04

overall response rate PTCL: 40%; complete response rate PTCL: 40%; median duration of response PTCL: 17.3 months; overall response rate DLBCL: 67%; median duration of response DLBCL: not yet reached; duration of response DLBCL: out to 42 months

Read More

Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers Preliminary clinical data from patients with relapsed/refractory EBV + peripheral T-cell lymphoma in the pivotal N

Read More
Nana-val
EBV-associated cancers
Phase 1b/2
2023-10-04

overall response rate PTCL: 40%; complete response rate PTCL: 40%; median duration of response PTCL: 17.3 months; overall response rate DLBCL: 67%; median duration of response DLBCL: not yet reached; duration of response DLBCL: out to 42 months

Read More

Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers Preliminary clinical data from patients with relapsed/refractory EBV + peripheral T-cell lymphoma in the pivotal N

Read More
Nana-val
EBV-associated cancers
Phase 1b/2
2023-10-04

overall response rate PTCL: 40%; complete response rate PTCL: 40%; median duration of response PTCL: 17.3 months; overall response rate DLBCL: 67%; median duration of response DLBCL: not yet reached; duration of response DLBCL: out to 42 months

Read More

Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers Preliminary clinical data from patients with relapsed/refractory EBV + peripheral T-cell lymphoma in the pivotal N

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in VIRX
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
VIRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How VIRX ranks across every disease it competes in
Competitive Position is a premium feature
See how VIRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial